Академический Документы
Профессиональный Документы
Культура Документы
1451
lated to the middle ear. It applies only to the otherwise healthy child without underlying conditions
that may alter the natural course of AOM. These
conditions include, but are not limited to, anatomic
abnormalities such as cleft palate, genetic conditions
such as Down syndrome, immunodeficiencies, and
the presence of cochlear implants. Also excluded are
children with a clinical recurrence of AOM within 30
days or AOM with underlying chronic otitis media
with effusion (OME).
METHODS
To develop the clinical practice guideline on the management
of AOM, the American Academy of Pediatrics (AAP) and American Academy of Family Physicians (AAFP) convened the Subcommittee on Management of Acute Otitis Media, a working
panel composed of primary care and subspecialty physicians. The
subcommittee was cochaired by a primary care pediatrician and a
family physician and included experts in the fields of general
pediatrics, family medicine, otolaryngology, epidemiology, infectious disease, and medical informatics. All panel members reviewed the AAP policy on conflict of interest and voluntary disclosure and were given an opportunity to present any potential
conflicts with the subcommittees work.
The AAP and AAFP partnered with the Agency for Healthcare
Research and Quality (AHRQ) and the Southern California Evidence-Based Practice Center to develop the evidence report, which
served as a major source of data for these practice guideline
recommendations.1 Specific clinical issues addressed in the AHRQ
evidence report were the 1) definition of AOM, 2) natural history
of AOM without antibacterial treatment, 3) effectiveness of antibacterial agents in preventing clinical failure, and 4) relative effectiveness of specific antibacterial regimens. The AHRQ report
focused on children between 4 weeks and 18 years of age with
uncomplicated AOM seeking initial treatment. Outcomes included the presence or absence of signs and symptoms within 48
hours, at 3 to 7 days, 8 to 14 days, 15 days to 3 months, and more
than 3 months and the presence of adverse effects from antibacterial treatment. Southern California Evidence-Based Practice Center project staff searched Medline (1966 through March 1999), the
Cochrane Library (through March 1999), HealthSTAR (1975
through March 1999), International Pharmaceutical Abstracts
(1970 through March 1999), CINAHL (1982 through March 1999),
BIOSIS (1970 through March 1999), and Embase (1980 through
March 1999). Additional articles were identified by review of
reference lists in proceedings, published articles, reports, and
TABLE 1.
RECOMMENDATION 1
To diagnose AOM the clinician should confirm a history of acute onset, identify signs of middle-ear effusion
(MEE), and evaluate for the presence of signs and symptoms of middle-ear inflammation. (This recommendation
is based on observational studies and a preponderance of
benefit over risk; see Table 2.)
Definition
Implication
Strong recommendation
Recommendation
Option
No recommendation
1452
TABLE 2.
Definition of AOM
1453
TABLE 3.
Acetaminophen, ibuprofen
Tympanostomy/myringotomy31
RECOMMENDATION 2
The management of AOM should include an assessment of pain. If pain is present, the clinician should
recommend treatment to reduce pain. (This is a strong
recommendation based on randomized, clinical trials with
limitations and a preponderance of benefit over risk.)
Many episodes of AOM are associated with pain.23
Although pain is an integral part of the illness, clinicians often see otalgia as a peripheral concern not
requiring direct attention.24 The AAP published the
policy statement The Assessment and Management
of Acute Pain in Infants, Children, and Adolescents25 to assist the clinician in addressing pain in
the context of illness. The management of pain, especially during the first 24 hours of an episode of
AOM, should be addressed regardless of the use of
antibacterial agents.
Various treatments of otalgia have been used, but
none has been well studied. The clinician should
select a treatment based on a consideration of benefits and risks and, wherever possible, incorporate
parent/caregiver and patient preference (Table 3).
RECOMMENDATION 3A
Comments
Effective analgesia for mild to moderate pain,
readily available, mainstay of pain
management for AOM
May have limited effectiveness
Certain Diagnosis
6 mo
6 mo to 2 y
Antibacterial therapy
Antibacterial therapy
2 y
Antibacterial therapy
if severe illness;
observation option*
if nonsevere illness
Uncertain Diagnosis
Antibacterial therapy
Antibacterial therapy
if severe illness;
observation
option* if
nonsevere illness
Observation option*
This table was modified with permission from the New York State
Department of Health and the New York Region Otitis Project
Committee.32,33
* Observation is an appropriate option only when follow-up can
be ensured and antibacterial agents started if symptoms persist or
worsen. Nonsevere illness is mild otalgia and fever 39C in the
past 24 hours. Severe illness is moderate to severe otalgia or fever
39C. A certain diagnosis of AOM meets all 3 criteria: 1) rapid
onset, 2) signs of MEE, and 3) signs and symptoms of middle-ear
inflammation.
1455
TABLE 5.
Initial
Antibacterial
Therapy
Initial
Observation
P Value
60%
91%
79%
82%
2.8
0.5
2.3
2.0
0.59%
59%
87%
71%
72%
3.3
1.4
4.1
3.0
0.17%
NS
NS
NS
NS
NS
.001
.004
.004
NS
45%
21%
16%
48%
26%
NS
NS
2%
1457
Tympanocentesis, clindamycin
Non-type I: ceftriaxone, 3
days; type I: clindamycin
Ceftriaxone, 1 or 3
days
Amoxicillin-clavulanate,
90 mg/kg per day of
amoxicillin, with 6.4
mg/kg per day of
clavulanate
Yes
Amoxicillin,
clavulanate, 90
mg/kg per day
of amoxicillin,
with 6.4 mg/kg
per day of
clavulanate
Ceftriaxone, 1 or 3 days
Amoxicillin-clavulanate,
90 mg/kg per day of
amoxicillin
component, with 6.4
mg/kg per day of
clavulanate
Ceftriaxone, 3 days
Non-type I: cefdinir,
cefuroxime,
cefpodoxime; type I:
azithromycin,
clarithromycin
Non-type I: cefdinir,
cefuroxime,
cefpodoxime; type
I: azithromycin,
clarithromycin
Amoxicillin, 8090 mg/
kg per day
No
Amoxicillin, 8090
mg/kg per day
Temperature
39C and/or
Severe
Otalgia
TABLE 6.
Recommended Antibacterial Agents for Patients Who Are Being Treated Initially With Antibacterial Agents or Have Failed 48 to 72 Hours of Observation or Initial Management With
Antibacterial Agents
No recommendations for complementary and alternative medicine (CAM) for treatment of AOM are made
based on limited and controversial data.
Increasing numbers of parents/caregivers are using various forms of nonconventional treatment for
their children.128,129 The types of treatments used can
differ depending on the ethnic background and belief system of the family and the availability of alternative medicine in a particular community. Treat-
1459
Fig 1. Continued.
complementary or alternative treatments.132 Although most treatments are harmless, some are not.
Some treatments can have a direct and dangerous
effect, whereas others may interfere with the effects
of conventional treatments.30 Clinicians should become more informed about CAM, ask whether they
are being used, and be ready to discuss potential
benefits or risks.133
To date there are no studies that conclusively show
a beneficial effect of alternative therapies used for
AOM. Recent interest in the use of CAM has led to
research efforts to investigate its efficacy.134 It is difficult to design and conduct studies on certain forms
of CAM because of the unique nature of the treatment.135 Any study conducted will need to show
proof of effectiveness of a specific therapy when
compared with the natural history of AOM. Conclusions regarding CAM cannot be made until research
evidence is available.
FUTURE RESEARCH
doses of medication shown to achieve adequate levels in the middle ear to treat the target organisms
successfully; and stratify outcomes by age and severity of illness. In addition, studies done in limited
geographic areas must be replicated in other areas to
ensure generalizability.
Some of the studies that should be considered
include:
Additional validation of standard definitions of
AOM
New or improved technologies for objective diag-
nosis of MEE
Efficacy of education programs to improve clini-
1461
organisms of AOM
Additional studies on potential measures to prevent AOM
SUMMARY
This clinical practice guideline provides evidencebased recommendations for the definition and management of AOM in children from 2 months through
12 years of age without signs or symptoms of systemic illness unrelated to the middle ear. It emphasizes accurate diagnosis and adherence to a consistent definition of AOM. Management of the pain
associated with AOM is identified as an essential
aspect of care. An option to observe a select group of
children with AOM with symptomatic therapy for 48
to 72 hours is supported by evidence and may potentially lead to decreased use of antibacterial agents.
If a decision is made to treat with an antibacterial
agent, amoxicillin at a dose of 80 to 90 mg/kg per
day is recommended as the initial antibacterial agent
of choice for most children. Additional guidance is
given for choosing an antibacterial agent when an
alternative to amoxicillin is indicated. Also addressed is evidence related to the prevention of AOM
and the role of CAM in the treatment of AOM. The
recommendations are summarized in Fig. 1.
CONCLUSIONS
REFERENCES
1. Marcy M, Takata G, Chan LS, et al. Management of Acute Otitis Media.
Evidence Report/Technology Assessment No. 15. AHRQ Publication
No. 01-E010 Rockville, MD: Agency for Healthcare Research and
Quality; 2001
2. Schappert SM. Office visits for otitis media: United States, 197590.
Adv Data. 1992;214:118
3. Cherry DK, Woodwell DA. National ambulatory medical care survey:
2000 summary. Adv Data. 2002;328:132
4. McCaig LF, Besser RE, Hughes JM. Trends in antimicrobial prescribing
rates for children and adolescents. JAMA. 2002;287:3096 3102
5. Niemela M, Uhari M, Jounio-Ervasti K, Luotonen J, Alho OP, Vierimaa
E. Lack of specific symptomatology in children with acute otitis media.
Pediatr Infect Dis J. 1994;13:765768
6. Kontiokari T, Koivunen P, Niemela M, Pokka T, Uhari M. Symptoms
of acute otitis media. Pediatr Infect Dis J. 1998;17:676 679
7. Pelton SI. Otoscopy for the diagnosis of otitis media. Pediatr Infect Dis
J. 1998;17:540 543
8. Brookhouser PE. Use of tympanometry in office practice for diagnosis
of otitis media. Pediatr Infect Dis J. 1998;17:544 551
9. Kimball S. Acoustic reflectometry: spectral gradient analysis for improved detection of middle ear effusion in children. Pediatr Infect Dis J.
1998;17:552555
10. Barnett ED, Klein JO, Hawkins KA, Cabral HJ, Kenna M, Healy G.
Comparison of spectral gradient acoustic reflectometry and other diagnostic techniques for detection of middle ear effusion in children
with middle ear disease. Pediatr Infect Dis J. 1998;17:556 559
11. Block SL, Mandel E, McLinn S, et al. Spectral gradient acoustic reflectometry for detection of middle ear effusion by pediatricians and
parents. Pediatr Infect Dis J. 1998;17:560 564
12. Block SL, Pichichero ME, McLinn S, Aronovitz G, Kimball S. Spectral
gradient acoustic reflectometry: detection of middle ear effusion in
suppurative acute otitis media. Pediatr Infect Dis J. 1999;18:741744
13. Karma PH, Penttila MA, Sipila MM, Kataja MJ. Otoscopic diagnosis of
middle ear effusion in acute and non-acute otitis media. I. The value of
different otoscopic findings. Int J Pediatr Otorhinolaryngol. 1989;17:
37 49
14. Karma PH, Sipila MM, Kataja MJ, Penttila MA. Pneumatic otoscopy
and otitis media. II. Value of different tympanic membrane findings
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
and their combinations. In: Lim DJ, Bluestone CD, Klein JO, Nelson JD,
Ogra PL, eds. Recent Advances in Otitis Media: Proceedings of the Fifth
International Symposium. Burlington, ON, Canada: Decker Periodicals;
1993:41 45
Merifield DO, Miller GS. The etiology and clinical course of bullous
myringitis. Arch Otolaryngol. 1966;84:487 489
Klein JO, McCracken GH Jr. Introduction: current assessments of
diagnosis and management of otitis media. Pediatr Infect Dis J. 1998;
17:539
Pichichero ME, Poole MD. Assessing diagnostic accuracy and tympanocentesis skills in the management of otitis media. Arch Pediatr Adolesc Med. 2001;155:11371142
Pichichero ME. Diagnostic accuracy, tympanocentesis training performance, and antibiotic selection by pediatric residents in management
of otitis media. Pediatrics. 2002;110:1064 1070
Chonmaitree T. Viral and bacterial interaction in acute otitis media.
Pediatr Infect Dis J. 2000;19(suppl):S24 S30
Dowell SF, Marcy SM, Phillips WR, Gerber MA, Schwartz B. Otitis
mediaprinciples of judicious use of antimicrobial agents. Pediatrics.
1998;101:165171
Wald ER. Acute otitis media: more trouble with the evidence. Pediatr
Infect Dis J. 2003;22:103104
Rosenfeld RM. Diagnostic certainty for acute otitis media. Int J Pediatr
Otorhinolaryngol. 2002;64:89 95
Hayden GF, Schwartz RH. Characteristics of earache among children
with acute otitis media. Am J Dis Child. 1985;139:721723
Schechter NL. Management of pain associated with acute medical
illness. In: Schechter NL, Berde CB, Yaster M, eds. Pain in Infants,
Children, and Adolescents. Baltimore, MD: Williams & Wilkins; 1993:
537538
American Academy of Pediatrics, Committee on Psychosocial Aspects
of Child and Family Health; Task Force on Pain in Infants, Children,
and Adolescents. The assessment and management of acute pain in
infants, children, and adolescents. Pediatrics. 2001;108:793797
Bertin L, Pons G, dAthis P, et al. A randomized, double-blind, multicentre controlled trial of ibuprofen versus acetaminophen and placebo for symptoms of acute otitis media in children. Fundam Clin
Pharmacol. 1996;10:387392
Hoberman A, Paradise JL, Reynolds EA, Urkin J. Efficacy of Auralgan
for treating ear pain in children with acute otitis media. Arch Pediatr
Adolesc Med. 1997;151:675 678
Sarrell EM, Mandelberg A, Cohen HA. Efficacy of naturopathic extracts in the management of ear pain associated with acute otitis
media. Arch Pediatr Adolesc Med. 2001;155:796 799
Barnett ED, Levatin JL, Chapman EH, et al. Challenges of evaluating
homeopathic treatment of acute otitis media. Pediatr Infect Dis J. 2000;
19:273275
Jacobs J, Springer DA, Crothers D. Homeopathic treatment of acute
otitis media in children: a preliminary randomized placebo-controlled
trial. Pediatr Infect Dis J. 2001;20:177183
Rosenfeld RM, Bluestone CD. Clinical efficacy of surgical therapy. In:
Rosenfeld RM, Bluestone CD, eds. Evidence-Based Otitis Media. 2nd ed.
Hamilton, ON, Canada: BC Decker Inc; 2003:227240
New York Region Otitis Project. Observation Option Toolkit for Acute
Otitis Media. Publication No. 4894. New York, NY: State of New York,
Department of Health; 2002
Rosenfeld RM. Observation option toolkit for acute otitis media. Int
J Pediatr Otorhinolaryngol. 2001;58:1 8
Rosenfeld RM, Vertrees JE, Carr J, et al. Clinical efficacy of antimicrobial drugs for acute otitis media: metaanalysis of 5400 children from
thirty-three randomized trials. J Pediatr. 1994;124:355367
Del Mar C, Glasziou P, Hayem M. Are antibiotics indicated as initial
treatment for children with acute otitis media? A meta-analysis. BMJ.
1997;314:1526 1529
Glasziou PP, Del Mar CB, Hayem M, Sanders SL. Antibiotics for acute
otitis media in children. Cochrane Database Syst Rev. 2000;4:CD000219
Rosenfeld RM, Kay D. Natural history of untreated otitis media. In:
Rosenfeld RM, Bluestone CD, eds. Evidence-Based Otitis Media. 2nd ed.
Hamilton, ON, Canada: BC Decker Inc; 2003:180 198
Appelman CL, Van Balen FA, Van de Lisdonk EH, Van Weert HC,
Eizenga WH. Otitis media acuta. NHG-standaard (eerste herziening)
[in Dutch]. Huisarts Wet. 1999;42:362366
van Buchem FL, Peeters MF, vant Hof MA. Acute otitis media: a new
treatment strategy. Br Med J (Clin Res Ed). 1985;290:10331037
Little P, Gould C, Williamson I, Moore M, Warner G, Dunleavey J.
Pragmatic randomised controlled trial of two prescribing strategies for
childhood acute otitis media. BMJ. 2001;322:336 342
1463
1464
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
triple sulfonamide, and placebo in 280 patients with acute otitis media
under two and one-half years of age. Clin Pediatr (Phila). 1972;11:
205214
Klein JO. Microbiologic efficacy of antibacterial drugs for acute otitis
media. Pediatr Infect Dis J. 1993;12:973975
Barnett ED, Klein JO. The problem of resistant bacteria for the management of acute otitis media. Pediatr Clin North Am. 1995;42:509 517
Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Pankuch GA, Appelbaum
PC. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents, based on pharmacodynamic
parameters: 1997 U.S. Surveillance study. Antimicrob Agents Chemother.
1999;43:19011908
Wald ER, Mason EO Jr, Bradley JS, Barson WJ, Kaplan SL, US Pediatric
Multicenter Pneumococcal Surveillance Group. Acute otitis media
caused by Streptococcus pneumoniae in childrens hospitals between
1994 and 1997. Pediatr Infect Dis J. 2001;20:34 39
Kellner JD, Ford-Jones EL. Streptococcus pneumoniae carriage in children
attending 59 Canadian child care centers. Toronto Child Care Centre
Study Group. Arch Pediatr Adolesc Med. 1999;153:495502
Green SM, Rothrock SG. Single-dose intramuscular ceftriaxone for
acute otitis media in children. Pediatrics. 1993;91:2330
Leibovitz E, Piglansky L, Raiz S, Press J, Leiberman A, Dagan R.
Bacteriologic and clinical efficacy of one day vs. three day intramuscular ceftriaxone for treatment of nonresponsive acute otitis media in
children. Pediatr Infect Dis J. 2000;19:1040 1045
Paradise JL. Short-course antibacterial treatment for acute otitis media:
not best for infants and young children. JAMA. 1997;278:1640 1642
Hoberman A, Paradise JL, Burch DJ, et al. Equivalent efficacy and
reduced occurrence of diarrhea from a new formulation of
amoxicillin/clavulanate potassium (Augmentin) for treatment of acute
otitis media in children. Pediatr Infect Dis J. 1997;16:463 470
Cohen R, Levy C, Boucherat M, Langue J, de la Rocque F. A multicenter, randomized, double-blind trial of 5 versus 10 days of antibacterial agent therapy for acute otitis media in young children. J Pediatr.
1998;133:634 639
Cohen R, Levy C, Boucherat M, et al. Five vs. ten days of antibiotic
therapy for acute otitis media in young children. Pediatr Infect Dis J.
2000;19:458 463
Pessey JJ, Gehanno P, Thoroddsen E, et al. Short course therapy with
cefuroxime axetil for acute otitis media: results of a randomized multicenter comparison with amoxicillin/clavulanate. Pediatr Infect Dis J.
1999;18:854 859
Pichichero ME, Marsocci SM, Murphy ML, Hoeger W, Francis AB,
Green JL. A prospective observational study of 5-, 7-, and 10-day
antibiotic treatment for acute otitis media. Otolaryngol Head Neck Surg.
2001;124:381387
Dowell SF, Butler JC, Giebink SG, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistancea report
from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J. 1999;18:19
Leiberman A, Leibovitz E, Piglansky L, et al. Bacteriologic and clinical
efficacy of trimethoprim-sulfamethoxazole for the treatment of acute
otitis media. Pediatr Infect Dis J. 2001;20:260 264
Daly KA, Giebink GS. Clinical epidemiology of otitis media. Pediatr
Infect Dis J. 2000;19(suppl 5):S31S36
Paradise JL, Rockette HE, Colborn DK, et al. Otitis media in 2253
Pittsburgh-area infants: prevalence and risk factors during the first two
years of life. Pediatrics. 1997;99:318 333
Kero P, Piekkala P. Factors affecting the occurrence of acute otitis
media during the first year of life. Acta Paediatr Scand. 1987;76:618 623
Curns AT, Holman RC, Shay DK, et al. Outpatient and hospital visits
associated with otitis media among American Indian and Alaska Native children younger than 5 years. Pediatrics. 2002;109(3). Available at:
www.pediatrics.org/cgi/content/full/109/3/e41
Casselbrant ML, Mandel EM, Fall PA, et al. The hereditability of otitis
media: a twin and triplet study. JAMA. 1999;282:21252130
Uhari M, Mantysaari K, Niemela M. A meta-analytic review of the risk
factors for acute otitis media. Clin Infect Dis. 1996;22:1079 1083
Adderson EE. Preventing otitis media: medical approaches. Pediatr
Ann. 1998;27:101107
Brown CE, Magnuson B. On the physics of the infant feeding bottle
and middle ear sequela: ear disease in infants can be associated with
bottle feeding. Int J Pediatr Otorhinolaryngol. 2000;54:1320
Niemela M, Pihakari O, Pokka T, Uhari M. Pacifier as a risk factor for
acute otitis media: a randomized, controlled trial of parental counseling. Pediatrics. 2000;106:483 488
117. Etzel RA, Pattishall EN, Haley NJ, Fletcher RH, Henderson FW. Passive smoking and middle ear effusion among children in day care.
Pediatrics. 1992;90:228 232
118. Ilicali OC, Keles N, Deger K, Savas I. Relationship of passive cigarette
smoking to otitis media. Arch Otolaryngol Head Neck Surg. 1999;125:
758 762
119. Wellington M, Hall CB. Pacifier as a risk factor for acute otitis media
[letter]. Pediatrics. 2002;109:351
120. Paradise JL, Ah-Tye C. Positional otitis media and otorrhea after
tympanostomy-tube placement [letter]. Pediatrics. 2002;109:349 350
121. Clements DA, Langdon L, Bland C, Walter E. Influenza A vaccine
decreases the incidence of otitis media in 6- to 30-month-old children
in day care. Arch Pediatr Adolesc Med. 1995;149:11131117
122. Belshe RB, Gruber WC. Prevention of otitis media in children with live
attenuated influenza vaccine given intranasally. Pediatr Infect Dis J.
2000;19(suppl 5):S66 S71
123. Hoberman A, Greenberg DP, Paradise JL, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young
children: a randomized controlled trial. JAMA. 2003;290:1608 1616
124. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate
vaccine against acute otitis media. N Engl J Med. 2001;344:403 409
125. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children.
Pediatr Infect Dis J. 2000;19:187195
126. Jacobs MR. Prevention of otitis media: role of pneumococcal conjugate
vaccines in reducing incidence and antibiotic resistance. J Pediatr.
2002;141:287293
127. Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of
the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis
J. 2003;22:10 16
128. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. N Engl J Med.
1993;328:246 252
129. Eisenberg DM, Davis R, Ettner S, et al. Trends in alternative medicine
use in the United States, 1990 1997: results of a follow-up national
survey. JAMA. 1998;280:1569 1575
130. Spigelblatt L, Laine-Ammara G, Pless IB, Guyver A. The use of alternative medicine by children. Pediatrics. 1994;94:811 814
131. Angell M, Kassirer JP. Alternative medicinethe risks of untested and
unregulated remedies. N Engl J Med. 1998;339:839 841
132. Kemper KJ. The Holistic Pediatrician: A Parents Comprehensive Guide to
Safe and Effective Therapies for the 25 Most Common Childhood Ailments.
New York, NY: Harper Perennial; 1996
133. American Academy of Pediatrics, Committee on Children With Disabilities. Counseling families who choose complementary and alternative medicine for their child with chronic illness or disability. Pediatrics.
2001;107:598 601
134. Grimm W, Muller HH. A randomized controlled trial of the effect of
fluid extract of Echinacea purpurea on the incidence and severity of
colds and respiratory infections. Am J Med. 1999;106:138 143
135. Barret B, Vohmann M, Calabrese C. Echinacea for upper respiratory
infection. J Fam Pract. 1999;48:628 635
136. van Buchem FL, Dunk JH, vant Hof MA. Therapy of acute otitis
media: myringotomy, antibiotics, or neither? A double-blind study in
children. Lancet. 1981;2(8252):883 887
1465
References
Citations
Post-Publication
Peer Reviews (P3Rs)
Subspecialty Collections
Reprints
The online version of this article, along with updated information and services, is
located on the World Wide Web at:
/content/113/5/1451.full.html